Inclusion Criteria:

- Signed written informed consent

- Age ≥ 18 years

- Patients with confirmed solid tumor and scheduled to receive at least two cycles of
myelosuppressive chemotherapy on Day 1 every 21 days at the same dosage and schedule
in the study.

- Experienced thrombocytopenia as evidenced by a platelet count < 100 Gi/L in the
preceding cycle immediately before study enrollment.

- ECOG performance status ≤ 2

- For females, surgically sterilized, postmenopausal or agree to use an acceptable form
of birth control

- Patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib,
trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by
the investigator and after consultation and approval from the Sponsor

- PT/INR and aPTT are within 80% to 120% of the normal range

Exclusion Criteria:

- Experienced thrombocytopenia as evidenced by a platelet count < 25 Gi/L at any time
in the preceding cycle immediately before enrollment into the study

- History or presence of clinically significant disease

- Received any TRAs, or rHuIL-11 within the last 4 weeks prior to screening

- Had received a bone marrow or peripheral blood stem cell infusion (within 1 year of
screening).

- Pregnant, wanting to become pregnant or lactating